ABSTRACT

Mycosis fungoides (MF) is the most common cutaneous lymphoma, accounting for 50% of all cutaneous lymphomas. Programmed death-1 (PD-1; CD279) is a marker of follicular helper T cells and is expressed by the neoplastic T cells of some types of malignant lymphoma, including MF. About 30% of primary cutaneous T-cell lymphomas are CD30 positive and have a broad spectrum from lymphomatoid papulosis to primary cutaneous anaplastic large cell lymphoma. CD30 expression in MF is important for diagnostic purposes, prognostic value, and a therapeutic perspective. In this study, PD-1 and CD30 expression in early MF lesions has been examined, and its relationship between prognosis and survival has been questioned. The byproducts could be unorthodox treatment options.

We prospectively applied immunohistochemically CD30 and PD-1 antibodies to the biopsies at our institution. We statistically evaluated the relationship between the expression rates of CD30 and PD-1 in atypical lymphocytes, with recurrence and survival.

This research with 119 patients was able to show a statistically significant relationship between CD30 and recurrence with PD-1 and poor survival.

When evaluated together with treatment options, CD30 and PD-1 are markers that may guide the clinical follow-up of aggressive MF cases.